ParametricsMedical

ensuring physicians have the best solutions for their patients



RESTORIGIN™

Amniotic Membrane Allograft for Wound Care Management

Restorigin is a placental tissue allograft that may be used as a protective barrier in wound care applications. The natural properties of amniotic tissue provide mechanical protection and growth factors to aid in the management of acute and chronic wounds.[1,2,3]

About Restorigin™

- **Non-Oriented**
  Restorigin is a dual layer amnion that offers the flexibility of placing either side toward the wound
- **Optimal Handling Characteristics**
  Easily controlled during application due to dual layer technology and 60 micron thickness
- **Natural Adherence**
  Adheres naturally to the patient's tissue without the need for sutures or other fixation

Safety and Processing

- **Gentle Processing**
  Minimally manipulated and processed using gentle detergents and water rinses
- **Gentle Sterility**
  Terminally sterilized with electron beam which has shorter exposure times and produces less free radicals, resulting in less deterioration to tissue structures

Versatility and Ease-of-Use

- **Convenient Storage**
  Restorigin is delivered and stored at room temperature with a 5-year shelf life
- **Preparation**
  Requires no up front preparation or hydration
- **Dual Layer Technology**
  Provides orientation placement flexibility
- **Multiple Sizes**
  Available in a variety of sizes to accommodate physician preferences



Restorigin™ Dual Layer Amnion Membrane

Why Restorigin™?

- **Proven Results**
  Restorigin has been shown to be effective in the management of chronic, non-healing wounds including diabetic and venous leg ulcers.



Figure 1. An average of 94.6% of wound area reduction was observed after 8 weeks of HAM sheet therapy.

In a 10 patient case series, 95% of wound closure was achieved after 8 weeks of treatment in patients who previously failed standard care protocols.[4]

Healing Progression - Before and After Treatment



Figure 2. Healing progression is shown for a 42-year-old female patient from before the treatment (A) to complete closure after 4.5 weeks of Human Amniotic Membrane therapy and a single graft application) (C).

Restorigin™ Product Information and Available Sizes

Product Number	Description	Size	Q Code
RGN-AM-0202	Restorigin Amnion Membrane	2x2cm	Q4191
RGN-AM-0203	Restorigin Amnion Membrane	2x3cm	Q4191
RGN-AM-0303	Restorigin Amnion Membrane	3x3cm	Q4191
RGN-AM-0404	Restorigin Amnion Membrane	4x4cm	Q4191
RGN-AM-0406	Restorigin Amnion Membrane	4x6cm	Q4191

1. Rowlatt, U. (1979). Intrauterine wound healing in a 20-week human fetus. Virchows Arch A Pathol Anat Histol, 381(3), 353–361.
2. Coolen, N.A. et al. (2010). Comparison between human fetal and adult skin. Archives of Dermatological Research, 302(1), 47–55.
3. Niknejad H, Peirovi H, Jorjani M, et al. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cell Mater. 2008;15:88-89.
4. Zakharova M, Hall B, Schallenberger M, Bangart K, Bangart D, Moore S, Thomas J: Case study report of chronic non-healing foot ulcers treated with dehydrated human amniotic membrane sheet. SAWC Spring 2020.

ParametricsMedical

ensuring physicians have the best solutions for their patients

800.917.4880 | nst@parametricsmedical.com | 1501 Leander Dr. Ste. 140, Leander, TX 78641 | parametricsmedical.com